November 8, 2023

John Shiver

John Shiver is chief strategy officer at IGM Biosciences – Infectious Diseases Business Unit. He has more than 26 years of vaccine and pharmaceutical R&D experience in industry and government labs. Before joining IGM Biosciences, he was senior vice president of global vaccine R&D at Sanofi Pasteur, and prior to joining Sanofi Pasteur, he led vaccine research at Merck and served in the experimental immunology branch of the National Institutes of Health (NIH).

Throughout his career, Shiver has led teams of scientists to develop novel vaccine and monoclonal antibody candidates against a broad range of diseases, which has contributed to the licensure of several new vaccines against HPV, rotavirus, zoster, dengue, as well as the combined measles, mumps, rubella, and varicella pediatric vaccine.

Shiver is a fellow of the American Academy of Microbiology and the International Society for Vaccines, and a member of the NIH HIV-1 Vaccine Testing Network Laboratory Science Advisory Committee and the Scientific Advisory Board of the Seattle Biomedical Research Institute. He is an adjunct professor at the University of Pennsylvania College of Medicine and a member of the editorial board of Nature Partner Journals (npj) Vaccines.

He holds a B.S. in chemistry/mathematics from Wofford College and a Ph.D. in physical chemistry from the University of Florida.